Financing channel feed – Endpoints News

Financing channel feed

Cell therapy biotech from Stanford CAR-T leader Crystal Mackall nabs $200M for PhII

3 years ago

TandemAI raises $35M in Series A for small molecule discovery, wet labs

3 years ago

A gene editing 3.0 player goes deep on cash, frontier science to put precision epigenetics to the big test

3 years ago

Regenerative cell biotech Thymmune launches with backing from George Church, John Maraganore

3 years ago

In push to expand its CAR-T therapies to US, China biotech Oricell raises additional $45M

3 years ago

Apellis jumps on the cash train after FDA approves its GA drug

3 years ago

Tangled in bankruptcy proceedings and legal tussle, Sorrento secures $75M to stay afloat

3 years ago

A small Connecticut biotech throws hat into IPO ring

3 years ago

Rare blood disorders biotech Hemab raises $135M, begins trek into clinic

3 years ago

Exclusive: Sanofi, Astellas venture arms add cash to Avilar's 'ATAC' mission

3 years ago

'Rare outliers': Feng Zhang eyes a new path to genetic medicine delivery with ex-Alnylam leaders and $193M

3 years ago

The top 100 biotech VCs: Who's staying at the table and what do they want now?

3 years ago

Working its way through a CRL on lead drug, Supernus taps $150M loan

3 years ago

Alexis Borisy, Zach Weinberg debut $520M idea for a new biotech investing model

3 years ago

Sesen Bio reaches deal with investor group, paving way for Carisma merger

3 years ago

A Texas-based biotech becomes the latest to enter the SPAC scene

3 years ago

PROTACs to RIPTACs: Arvinas founder snags $76M for next bet, Halda Therapeutics

3 years ago

Replay partners with MD Anderson’s Katy Rezvani, heads to clinic with new TCR NK cell company

3 years ago

Third time’s the charm: Cerevance’s Series B expands again

3 years ago

New SPAC submits plans for $130M IPO, as another raises $60M

3 years ago

IPO Friday: Hypertension drugmaker Mineralys maps out $192M Nasdaq debut

3 years ago

Prokarium raises $30M, pushes new bacteria immunotherapy for bladder cancer to clinic

3 years ago

Non-opioid drug developer snags PhIII funds; aTyr and Spruce line up capital

3 years ago

Swiss rare disease biotech withdraws IPO to update its Nasdaq plans

3 years ago

First page Previous page 38 39 404142 43 44 Next page Last page